Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.1    
    

CERTIFICATE OF AMENDMENT TO THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF GENAISSANCE PHARMACEUTICALS, INC.  

        Genaissance Pharmaceuticals, Inc., a Delaware corporation (the "Corporation"), pursuant to authority conferred on the Board of Directors of the Corporation
by the Amended and Restated Certificate of Incorporation of the Corporation (the "Certificate of Incorporation") and in accordance with the provisions of the General Corporation Law of the State of
Delaware, does hereby certify as follows: 

        FIRST:
That the Certificate of Incorporation was filed with the office of the Secretary of State of the State of Delaware on February 24, 1992. 

        SECOND:
That Section (a) of Paragraph 3 of the Certificate of Designations of the Preferred Stock of Genaissance Pharmaceuticals, Inc. to be Designated
Series A Preferred Stock is hereby amended to read, in its entirety, as follows: 

	3.
	Voting
Rights.

	(a)
	General. The holders of the series A preferred stock shall be entitled to notice of all stockholders meetings in accordance with
the Bylaws of the Corporation, and except as otherwise required by applicable law or in this Section 3, the holders of the series A
preferred stock shall be entitled to vote on all matters submitted to the stockholders of the Corporation for a vote, voting as a single class with the Common, with the holders of series A
preferred stock entitled to 0.88 of one vote for each share of Common issuable upon conversion of the series A preferred stock held as of the record date for such vote or, if no record date is
specified, as of the date of such vote or date of any written consent, as the case may be; provided that, notwithstanding anything to the contrary
herein, upon conversion, each share of Common issued shall be entitled to one vote per share. 

        THIRD:
The foregoing amendment to the Certificate of Incorporation was duly adopted by the Board of Directors and by the stockholders of the Corporation in accordance with the provisions
of Section 242 of the General Corporation Law of the State of Delaware. 

*******

        IN
WITNESS WHEREOF, the undersigned has signed this Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Genaissance Pharmaceuticals, Inc. on
behalf of the Corporation this 1st day of April, 2004. 

	 	 	GENAISSANCE PHARMACEUTICALS, INC.
	

 	
 	

By:	
 	

/s/  KEVIN L. RAKIN      
 Kevin L. Rakin, President

   Certificate of Designations of the Preferred Stock

Of

Genaissance Pharmaceuticals, Inc.

To be Designated

Series A Preferred Stock  

        Genaissance Pharmaceuticals, Inc., a Delaware corporation (the "Corporation"), pursuant to authority conferred on the Board of Directors of the Corporation
by the Amended and Restated Certificate of Incorporation of the Corporation (the "Certificate of Incorporation") and in accordance with the provisions of Section 151 of the General Corporation
Law of the State of Delaware (the "DGCL"), certifies that the Board of Directors of the Corporation, by unanimous written consent in accordance with the provisions of
Section 141(f) of the DGCL, duly adopted the following resolution: 

        RESOLVED:
That, pursuant to the authority expressly granted to and vested in the Board of Directors of the Corporation in accordance with the provisions of its Certificate of
Incorporation, a series of Preferred Stock of the Corporation be and hereby is established, consisting of 460,000 shares, to be designated "Series A Preferred Stock" (hereinafter
"Series A Preferred Stock"); that the Board of Directors be and hereby is authorized to issue such shares of Series A Preferred Stock from time to time and for such consideration and on
such terms as the Board of Directors shall determine; and that, subject to the limitations provided by law and by the Certificate of Incorporation, the powers, designations, preferences and relative,
participating, optional or other special rights of, and the qualifications, limitations or restrictions upon, the Series A Preferred Stock shall be as follows: 

        1.     Designation,
Par Value and Number. 460,000 shares of authorized Preferred Stock of the Corporation are hereby designated as "Series A
Preferred Stock" and constituted as a series of preferred stock, having a par value of $.001 per share (the "Series A Preferred Stock"). In
accordance with the terms hereof, each share of Series A Preferred Stock shall have the same relative rights as and be identical in all respects with each other share of Series A
Preferred Stock. 

        2.     Dividends.
To the extent permitted under the Delaware General Corporation Law, the Corporation shall pay dividends to the holders of the
Series A Preferred Stock as provided in this Section 2. 

        (a)   General.
Dividends on each issued and outstanding share of Series A Preferred Stock shall accrue at a rate of 2% per annum (subject
to Section 4(c) and Section 6(b)) on the Accreted Value of such share of Series A Preferred Stock as of the immediately
preceding Dividend Payment Date (or, for the initial Dividend Period, as of the Original Issuance Date) from and including the Original Issuance Date of such share of Series A Preferred Stock
until the first to occur of (i) the date on which the Liquidation
Value or the Make-Whole Redemption Price of such share of Series A Preferred Stock is paid to the holder thereof in accordance with Section 4,
(ii) the date on which such share of Series A Preferred Stock is converted into shares of Common in accordance with Section 5 (in which case, any
accrued dividends shall then be forfeited) or (iii) the date on which such share of Series A Preferred Stock is otherwise acquired by the Corporation. Such dividends shall accrue whether
or not they have been declared and whether or not there are profits, surplus or other funds of the Corporation legally available for the payment of dividends, and such dividends shall be cumulative
such that all accrued and unpaid dividends shall be fully paid or declared before any dividends may be made with respect to any Junior Securities. Dividends shall accrue on a daily basis (computed on
the basis of a 365-day year). 

        (b)   Payment
of Dividends. The Corporation shall pay, out of funds legally available therefor, any accrued dividends in respect of each share of
Series A Preferred Stock semi-annually in arrears on January 5 and July 5 of each year (each such date being a "Dividend Payment
Date" and each such semi-annual period ending on such Dividend Payment Date being a "Dividend Period"). Each such
dividend shall be payable to the holders of record of shares of Series A 

2

 

Preferred
Stock on December 15 and June 15, respectively, as they appear on the stock records of the Corporation at the close of business on such record date. An amount equal to any such
accrued dividends not paid with respect to any Dividend Period shall be added to the Accreted Value of the Series A Preferred Stock; provided, that, any such
amounts shall remain as accrued and unpaid dividends for all purposes hereunder notwithstanding such amounts being added to the Accreted Value. Such increased Accreted Value after each Dividend Period
shall be used for purposes of calculating dividends for succeeding Dividend Periods (except to the extent any such accrued dividends included in the Accreted Value are subsequently declared and paid). 

        (c)   Distribution
of Partial Dividend Payments. If at any time the Corporation pays less than the total amount of dividends then accrued with
respect to the Series A Preferred Stock, such payment shall be distributed pro rata among the holders of the outstanding shares of Series A Preferred Stock based upon the aggregate
dividends accrued and payable on such outstanding shares of Series A Preferred Stock held by each such holder. 

        (d)   Treatment
of Accrued and Unpaid Dividends Upon Conversion. Upon any conversion of shares of Series A Preferred Stock into Common in
accordance with Section 5, any accrued and unpaid dividends on the Series A Preferred Stock shall be forfeited. 

        (e)   Participation
in Common Dividends. In the event that the Corporation declares or pays a dividend or makes any distribution on the Common,
then the holders of the outstanding shares of Series A Preferred Stock (based on the number of shares of Common into which such shares of Series A Preferred Stock are convertible as of
the record date for such dividend or distribution) and the holders of the Common shall share pro rata in such dividend or distribution. 

        (f)    Partial
Dividend Period. Dividends payable on the shares of Series A Preferred Stock for any period less than a full Dividend Period
shall be computed on the basis of a 365-day year and the actual number of days elapsed in the period for which such dividend is payable. 

        3.     Voting
Rights. 

        (a)   General.
The holders of the Series A Preferred Stock shall be entitled to notice of all stockholders meetings in accordance with the
Bylaws of the Corporation, and except as otherwise required by applicable law or in this Section 3, the holders of the Series A Preferred Stock shall be
entitled to vote on all matters submitted to the stockholders of the Corporation for a vote, voting as a single class with the Common, with the holders of Series A Preferred Stock entitled to
one vote for each share of Common issuable upon conversion of the Series A Preferred Stock held as of the record date for such vote or, if no record date is specified, as of the date of such
vote or date of any written consent, as the case may be. 

        (b)   Special
Series A Preferred Stock Restrictions. In addition to the voting rights contained in
Section 3(a) or as otherwise required by applicable law, so long as the Investor or its Affiliates own in the aggregate at least 60,000 shares of Series A
Preferred Stock (as adjusted for any stock split, stock dividend, recapitalization or otherwise), the Corporation shall not, without the vote or written consent of the holders of 662/3%
of the shares of Series A Preferred Stock then outstanding (the "Supermajority Preferred Holders"): 

          (i)  alter
or change the rights, preferences or privileges of the Series A Preferred Stock, including any increase in the number of authorized shares of
Series A Preferred Stock, whether as a result of any amendment, repeal, modification or supplement to any provision of the Certificate of Incorporation of the Corporation, this Certificate of
Designation or the Bylaws of the Corporation, or by merger, consolidation or otherwise; 

         (ii)  except
for the issuance and sale of the Series A Preferred Stock pursuant to the Series A Purchase Agreement and the Warrant, authorize, issue or enter
into any agreement 

3

 

providing
for the issuance (contingent or otherwise) of any capital stock or other equity securities of the Corporation (or any securities convertible into or exchangeable for any capital stock or
other equity securities of the Corporation) having rights, preference, privileges or priorities pari passu with or senior to the Series A Preferred Stock (including
any issuances of Series A Preferred Stock other than pursuant to the Series A Purchase Agreement and the Warrant); 

        (iii)  pay,
or authorize or obligate the Corporation to pay, any dividend or make any other distribution in respect of any Junior Securities (other than a dividend payable
solely in shares of Common); 

        (iv)  directly
or indirectly redeem, purchase or otherwise acquire any of the Corporation's capital stock or other equity securities (including warrants, options and other
rights to acquire such capital stock or other equity securities) other than (A) the Series A Preferred Stock pursuant to the terms of this Certificate of Designation and
(B) shares of its capital stock or other equity securities repurchased or otherwise acquired (i) upon the termination of employment of an officer, employee, director or consultant of the
Corporation or (ii) in connection with the surrender of shares of capital stock or other equity securities, in each case pursuant to an option agreement or restricted stock purchase agreement
or comparable agreement approved by the Board); 

         (v)  (A)
liquidate, dissolve or wind up the Corporation, (B) commence a voluntary case under any applicable bankruptcy law, (C) consent to the appointment of,
or taking possession by, a receiver of the Corporation or for all or substantially all of the property and assets of the Corporation or (D) effect any general assignment for the benefit of
creditors of the Corporation; 

        (vi)  create,
incur, assume or suffer to exist any Indebtedness, except that the Corporation may incur Indebtedness if the amount of Indebtedness outstanding at such time
(including the Indebtedness so incurred) does not exceed (A) $7,000,000 at any time after the Warrant has been exercised by the Investor or (B) $11,000,000 at any time if the Warrant has
not been exercised by the Investor; 

       (vii)  create,
incur, assume or suffer to exist any Liens on the Corporation's assets, other than Permitted Liens; 

      (viii)  change
in any material way the nature of the Corporation's business; or 

        (ix)  agree
to do any of the foregoing. 

        4.     Liquidity
Events. 

        (a)   Significant
Event. Upon any Significant Event: 

          (i)  Each
holder of Series A Preferred Stock shall be entitled to receive for each share of Series A Preferred Stock held by such holder immediately prior to
such Significant Event, prior and in preference to any distribution or payment made upon or with respect to any Junior Securities, irrespective of whether such distribution or payment is made by the
Corporation or any other Person, an amount (the "Liquidation Value") equal to either (A)(1) the Accreted Value of such share of Series A
Preferred Stock on the date of distribution or payment plus (2) all dividends (whether or not declared) accrued since the end of the previous Dividend Period on
such share of Series A Preferred Stock or, (B) if elected by the Supermajority Preferred Holders, the amount to which the holder of such share of Series A Preferred Stock would be
entitled assuming all of the shares of Series A Preferred Stock had been converted into shares of Common in accordance with Section 5(a)(i) immediately prior
to such Significant Event. If upon any Significant Event the assets and/or proceeds to be 

4

 

distributed
to the holders of the Series A Preferred Stock are insufficient to permit payment to such holders of the aggregate amount which they are entitled to receive under
Section 4(a)(i)(A), then the entire amount of assets and/or proceeds available to the Corporation's stockholders upon such Significant Event shall be distributed
pro rata among such holders of the Series A Preferred Stock based upon the aggregate amounts due to each such holder with respect to such shares of Series A Preferred Stock if such
assets and/or proceeds were sufficient to permit payment in full. 

         (ii)  With
respect to any Significant Event involving the Corporation's merger, consolidation or similar transaction, except as otherwise consented to by the Supermajority
Preferred Holders, the Corporation shall not effect such Significant Event unless the agreement or plan of merger or consolidation or other applicable agreement provides that the consideration payable
to the stockholders of the Corporation shall be allocated among the holders of capital stock of the Corporation in accordance with the priorities set forth in this
Section 4(a). 

        (iii)  After
the payment and/or distribution to the holders of the Series A Preferred Stock of the amounts set forth in
Section 4(a)(i), the holders of the Series A Preferred Stock shall not be entitled to any further payment or distribution. 

        (b)   Form
of Consideration. Whenever the distribution provided for in this Section 4 shall be payable in
property other than cash, the value of such distribution shall be the Fair Market Value of such property. 

        (c)   Mandatory
Redemption Upon Certain Significant Events. If a Significant Event occurs prior to the fifth anniversary of the Closing Date,
then, unless the Supermajority Preferred Holders elect otherwise, the Corporation shall redeem each then outstanding share of Series A Preferred Stock at a per share purchase price equal to the
sum of (i) the Accreted Value of such shares of Series A Preferred Stock on the date of redemption, plus (ii) all dividends (whether or not declared)
accrued since the end of the previous Dividend Period on such share of Series A Preferred Stock, plus (iii) the sum of the remaining dividends that would
have accrued and/or been payable on one share of Series A Preferred Stock pursuant to Section 2 from the date of redemption pursuant to this
Section 4(c) through the fifth
anniversary of the Closing Date had such share of Series A Preferred Stock not been so redeemed (the sum of clauses (i), (ii) and (iii) being referred to herein as the
"Make-Whole Redemption Price"). If the Corporation (or its successor with respect to any Significant Event) does not have sufficient funds
legally available to redeem on any redemption date all shares of Series A Preferred Stock, the Corporation (or its successor) shall redeem a pro rata portion of each holder's shares of such
stock out of funds legally available therefor, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the legally available funds were sufficient
to redeem all such shares, and shall redeem the remaining shares to have been redeemed as soon as practicable after the Corporation (or its successor) has funds legally available therefor;
provided, that, with respect to any shares of Series A Preferred Stock that were to have been redeemed and are not, the Make-Whole Redemption Price
shall be re-calculated such that with respect to the remaining dividends determined in accordance with clause (iii) of this Section 4(c), the
dividend rate shall be increased to 10% per annum for purposes of Section 2(a) for any shares of Series A Preferred Stock that are not so redeemed. 

        5.     Conversion.

	(a)
	Conversion
Procedure. 

          (i)  Subject
to Section 5(c), at any time and from time to time, a holder of Series A Preferred Stock shall have the right to
convert any share(s) of Series A Preferred Stock into 

5

 

the
number of shares of Common computed by dividing (X) the Original Issue Price by (Y) the Conversion Price then in effect for such share of Series A
Preferred Stock. 

         (ii)  Each
conversion of Series A Preferred Stock pursuant to Section 5(a) shall be effected by delivery, to the office of the
Corporation or to any transfer agent for such shares, of (A) duly endorsed certificates for the shares being converted and (B) written notice to the Corporation that the holder elects to
convert such shares. Conversion pursuant to Section 5(a) shall be deemed to occur immediately prior to the close of business on the date the certificates and notice
are delivered. At the time any such conversion has been effected, the rights of the holders of shares of Series A Preferred Stock so converted shall cease with respect to such converted shares
of Series A Preferred Stock, and such holders entitled to receive Common upon conversion of such Series A Preferred Stock shall be treated for all purposes as the record holders of such
shares of Common on the date conversion is deemed to have been effected. 

        (iii)  As
soon as practicable after (x) a conversion has been effected and (y) the certificate(s) representing the converted shares of Series A Preferred
Stock have been surrendered to the principal office of the
Corporation or to any transfer agent for such shares, the Corporation shall deliver to the converting holder: 

	(A)
	a
certificate or certificates representing the number of shares of Common issuable by reason of such conversion in such name or names and such denomination or denominations as the
converting holder has specified;

	(B)
	a
certificate representing any shares of Series A Preferred Stock which were represented by the certificate or certificates delivered to the Corporation or to any transfer
agent in connection with such conversion but which were not converted; and

	(C)
	any
amount payable under Section 5(a)(vi) with respect to such conversion. 

        (iv)  The
Corporation shall not close its books on a Business Day against the transfer of Series A Preferred Stock or of Common issued or issuable upon conversion of
Series A Preferred Stock in any manner that interferes with the timely conversion of Series A Preferred Stock. At any time that a conversion of shares of Series A Preferred Stock
pursuant to this Section 5(a) has occurred, the shares of Series A Preferred Stock so converted shall not thereafter be reissued, sold or transferred or
deemed to be issued and outstanding for any purpose and the number of shares of Series A Preferred Stock authorized to be issued by the Corporation shall be reduced by the number of shares of
Series A Preferred Stock so converted. 

         (v)  The
Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Common, solely for the purpose of issuance upon the conversion
of shares of the Series A Preferred Stock, such number of shares of Common as are issuable upon the conversion of all outstanding Series A Preferred Stock. All shares of Common which are
so issuable shall, when issued in accordance with the terms hereof, be duly and validly issued, fully paid and nonassessable. The Corporation shall not take any action that would cause the number of
authorized but unissued shares of Common to be less than the number of such shares required to be reserved hereunder for issuance upon conversion of the Series A Preferred Stock. 

        (vi)  If
any fractional interest in a share of Common would, except for the provisions of this subparagraph, be delivered upon any conversion of any shares of Series A
Preferred Stock, the Corporation, in lieu of delivering the fractional share therefor, may pay an amount to the holder thereof equal to the Market Price of such fractional interest as of the date of
conversion. The determination as to the amount of any cash payment in lieu of the issuance 

6

 

of
fractional shares shall be based upon the total number of shares of Series A Preferred Stock being converted at any one time by the holder thereof, not upon each share of Series A
Preferred Stock being converted at any one time by the holder thereof. 

       (vii)  If
any holder surrenders shares of Series A Preferred Stock for conversion after the close of business on the record date for the payment of a dividend and
prior to the opening of business on the Dividend Payment Date for such dividend, then, notwithstanding such conversion, the dividend payable on such Dividend Payment Date will be paid to the
registered holder of such shares on such record date. 

      (viii)  If
a holder converts shares of Series A Preferred Stock, the Corporation shall pay any documentary, stamp or similar issue or transfer tax due on the issue of
Common upon the conversion. The holder, however, shall pay to the Corporation the amount of any tax which is due (or shall establish to the satisfaction of the Corporation the payment thereof or that
no such payment is due) if the shares are to be issued in a name other than the name of such holder. 

        (b)   Effect
on Conversion Price of Certain Events. For purposes of determining the applicable Conversion Price under
Section 5, the following shall be applicable: 

          (i)  Subdivisions
or Combinations of Common. If the Corporation at any time subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more
classes of its outstanding shares of Common into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision shall be reduced proportionately, and if the
Corporation at any time combines (by reverse stock split or otherwise) one or more classes of its outstanding shares of Common into a smaller number of shares, the Conversion Price in effect
immediately prior to such combination shall be increased proportionately. 

         (ii)  Recapitalization,
Reorganization, Reclassification, Consolidation, Merger or Sale. Any recapitalization, reorganization, reclassification, consolidation, merger or
similar transaction, in each case which is effected in such a manner that the holders of Common are entitled to receive (either directly or upon subsequent liquidation) stock, securities or assets
with respect to or in exchange for Common, and which does not otherwise qualify as a Fundamental Change, is referred to herein as an "Organic Change."
Prior to the consummation of any Organic Change, the Corporation shall make appropriate provisions to insure that each of the holders of Series A Preferred Stock shall thereafter
have the right to acquire and receive, in lieu of the shares of Common immediately theretofore acquirable and receivable upon the conversion of such holder's Series A Preferred Stock, such
shares of stock, securities or assets as such holder would have received in connection with such Organic Change if such holder had converted its Series A Preferred Stock immediately prior to
such Organic Change. In each such case, the Corporation shall also make appropriate provisions to insure that the provisions of this Section 5(b) shall thereafter
be applicable to the securities issuable upon conversion of the Series A Preferred Stock and shall provide the holders of Series A Preferred Stock with notice thereof. 

        (iii)  Notices.
As soon as practicable after any adjustment of the Conversion Price, the Corporation shall give written notice thereof to all holders of Series A
Preferred Stock, setting forth in reasonable detail and certifying the calculation of such adjustment. 

7

  

        (c)   Mandatory
Conversion. If, on or after the third anniversary of the Closing Date, the Market Price of the Common exceeds $7.00 (as adjusted
for any stock split, stock dividend, recapitalization or otherwise) for 23 consecutive Business Days, the Corporation may elect, beginning on the first Business Day following such 23 Business Day
period and at any time thereafter while any shares of Series A Preferred Stock remain outstanding, to require the holders of all (but not less than all) outstanding shares of Series A
Preferred Stock to convert such shares into Common pursuant to the terms of this Section 5 (a "Mandatory
Conversion"). In case of such election, the Corporation shall give written notice to each holder of outstanding shares of Series A Preferred Stock. Any such conversion
shall be deemed to have been effected, without further action by any party, immediately prior to the close of business on the fifth Business Day after the Corporation delivers notice of its election
of a Mandatory Conversion to the holders of Series A Preferred Stock Shares. At the time any such conversion has been effected, the rights of the holders of shares of Series A Preferred
Stock so converted shall cease with respect to such converted shares of Series A Preferred Stock, and such holders entitled to receive Common upon conversion of such Series A Preferred
Stock shall be treated for all purposes as the record holders of such shares of Common on the date conversion is deemed to have been effected. The provisions of
Section 5(a) (other than Section 5(a)(ii)) shall apply to a Mandatory Conversion under this
Section 5(c). 

        6.     Redemptions.

        (a)   Optional
Redemption. The Supermajority Preferred Holders shall have the right to require the Corporation to redeem all (but not less than
all) of the outstanding shares of Series A Preferred Stock on the third, fourth or fifth anniversary of the Closing Date. The Supermajority Preferred Holders shall elect such optional
redemption by delivering a written notice of such election to the Corporation (the "Redemption Notice") at least 30 calendar days prior to the
applicable anniversary date (the "Optional Redemption Date"). Subject to Section 6(b), the Corporation shall be
obligated to consummate the redemption of each outstanding share of Series A Preferred Stock on the applicable Optional Redemption Date by paying to each holder thereof a per share redemption
price (the "Redemption Price") in cash equal to (i) the Accreted Value of such share of Series A Preferred Stock on the Optional
Redemption Date plus (ii) all dividends (whether or not declared) accrued on such share of Series A Preferred Stock since the end of the previous Dividend
Period as of the Optional Redemption Date. If the Supermajority Preferred Holders do not elect to require the redemption of all outstanding shares of Series A Preferred Stock during the
redemption election periods described in this Section 6(a), then the Corporation shall have no further obligation under this
Section 6(a) to redeem any shares of Series A Preferred Stock, and any right of redemption contained in this Section 6(a)
shall be deemed to have expired and thereafter be null and void. 

        (b)   Deferral
of Redemption. If, upon any optional redemption election made by the Supermajority Preferred Holders pursuant to
Section 6(a), the available cash resources of the Corporation are (i) insufficient to permit payment to the holders of the Series A Preferred Stock of
the aggregate Redemption Price or (ii) sufficient, but the Corporation elects to defer payment to the holders of the Series A Preferred Stock of the aggregate Redemption Price under this
paragraph, then the Corporation shall have the option to defer the payment of such aggregate Redemption Price for a period of up to 12 months; provided, that,
during any such deferral period, the dividend rate for the Series A Preferred Stock shall be increased to 10% per annum for purposes of Section 2(a). If the
Corporation does not have sufficient funds legally available to redeem on any redemption date all shares of Series A Preferred Stock, the Corporation shall redeem a pro rata portion of each
holder's shares of such stock out of funds legally available therefor, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the legally available
funds were sufficient to redeem all such shares, and 

8

 

shall
redeem the remaining shares to have been redeemed as soon as practicable after the Corporation has funds legally available therefor; provided, that, during any such
period for which shares of Series A Preferred Stock were to have been redeemed and are not, the dividend rate for any outstanding shares of Series A Preferred Stock shall be increased to
10% per annum for purposes of Section 2(a). 

        (c)   Mandatory
Redemption. In addition to the mandatory redemption required by Section 4(c), upon the
occurrence of any of the following, the Corporation shall, unless the Supermajority Preferred Holders elect otherwise, redeem all of the outstanding shares of Series A Preferred Stock at a per
share purchase price equal to the Make-Whole Redemption Price: 

          (i)  the
failure of the Common to be quoted on the Nasdaq National Market of The Nasdaq Stock Market or listed on the New York Stock Exchange; 

         (ii)  the
Corporation issues any shares of Common (or any securities convertible into or exchangeable for Common) for a per share purchase price of less than $2.25 (as
adjusted for any stock split, stock dividend, recapitalization or otherwise) (other than (A) shares issued as consideration in a Permitted Acquisition and (B) shares issued pursuant to
the terms of any agreement outstanding on the date hereof and shares of capital stock, options, restricted stock or other stock based awards to purchase capital stock, issued to employees, directors,
advisors or consultants of the Corporation pursuant to a stock option, restricted stock or other stock based award or equity incentive plan approved by the Board); 

        (iii)  any
breach or inaccuracy in any representation or warranty of the Corporation (as determined as of the time such representation or warranty is made) contained in the
Series A Purchase Agreement or the Registration Rights Agreement that has a Material Adverse Effect, provided that such representations and warranties shall survive only until one year from the
date of this Certificate of Designation; 

        (iv)  any
breach by the Corporation of any of its covenants, or any failure of the Corporation to perform any of its obligations, in the Series A Purchase Agreement or
the Registration Rights Agreement that has a Material Adverse Effect; 

         (v)  (A)
an involuntary case shall be commenced against the Corporation and the petition shall not be dismissed, stayed, bonded or discharged within sixty
(60) calendar days after commencement of the case or a court having jurisdiction in the premises shall enter a decree or order for relief in respect of the Corporation in an involuntary case,
under any applicable bankruptcy, insolvency or other similar law now or hereinafter in effect, or any other similar relief shall be granted under any applicable federal, state, local or foreign law;
(B) a decree or order of a court having jurisdiction in the premises for the appointment of a receiver, liquidator, sequestrator, trustee, custodian or other officer having similar powers over
the Corporation or over all or a substantial part of the property of the Corporation shall be entered; (C) an interim receiver, trustee or other custodian of the Corporation or of all or a
substantial part of the property of the Corporation shall be appointed or a warrant of attachment, execution or similar process against any substantial part of the property of the Corporation shall be
issued and any such event shall not be stayed, dismissed, bonded or discharged within sixty (60) calendar days after entry, appointment or issuance; or (D) the Corporation shall
(1) commence a voluntary case under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect, (2) consent to the entry of an order for relief in an
involuntary case, or to the conversion of an involuntary case to a voluntary case, under any such law, (3) consent to the appointment of or taking possession by a receiver, trustee or other
custodian for all or a substantial part of its property, (4) make any assignment for the benefit of creditors or (5) take any corporate action to authorize any of the foregoing. 

9

 

        (vi)  any
default under the terms of any agreement under which the Corporation has incurred Indebtedness exceeding $500,000 (excluding any agreement entered into prior to
October 7, 2003); or 

       (vii)  failure
of the Corporation to in good faith (A) attempt to file a shelf registration statement on Form S-3 within 45 calendar days of
the Closing Date or (B) attempt to cause a shelf registration statement on Form S-3 to be declared effective by the Securities and Exchange Commission within 120 calendar
days of the Closing Date, in each case, registering for re-sale, among other securities, the shares of Common into which the shares of Series A Preferred Stock owned by the Investor
are convertible pursuant to Section 5. 

        (d)   Redeemed
Shares. All rights pertaining to shares of Series A Preferred Stock that are redeemed pursuant to this
Section 6 shall cease, and such shares shall not thereafter be (i) reissued, sold or transferred, (ii) entitled to any dividends accruing after the
date of redemption or (iii) deemed to be issued and outstanding for any purpose whatsoever. 

        7.     General.

        (a)   The
Corporation shall keep at its principal office (or at the office of its counsel) a register for the registration of Series A Preferred Stock. Upon the
surrender of any certificate representing Series A Preferred Stock at such place, the Corporation shall, at the request of the record holder of such certificate, execute and deliver a new
certificate or certificates in exchange therefor representing in the aggregate the number of shares represented by the surrendered certificate. Each such new certificate shall be registered in such
name and shall represent such number of shares as is requested by the holder of the surrendered certificate and shall be substantially identical in form to the surrendered certificate. 

        (b)   Upon
receipt of evidence reasonably satisfactory to the Corporation (an affidavit of the registered holder shall be satisfactory) of the ownership and the loss, theft,
destruction or mutilation of any certificate evidencing shares of Series A Preferred Stock, and in the case of any such loss, theft or destruction, upon receipt of indemnity reasonably
satisfactory to the Corporation (provided that if the holder is a financial institution or other institutional investor its own agreement shall be satisfactory), or, in the case of any such mutilation
upon surrender of such certificate, the Corporation shall execute and deliver in lieu of such certificate a new certificate of like kind representing the number of shares of such class represented by
such lost, stolen, destroyed or mutilated certificate and dated the date of such lost, stolen, destroyed or mutilated certificate. 

        (c)   Except
as otherwise expressly provided hereunder, all notices referred to herein shall be in writing and shall be delivered by registered or certified mail, return
receipt requested and postage prepaid, by reputable overnight courier service, charges prepaid, or by personal delivery, and shall be deemed to have been given (i) three (3) Business
Days after being sent by registered or certified mail, (ii) one (1) Business Day after being deposited with such an overnight courier service, and (iii) upon delivery, if by
personal delivery, if mailed or delivered (A) to the Corporation, at its principal executive offices, or (B) to any stockholder, at such holder's address as it appears in the stock
records of the Corporation (unless otherwise indicated by any such holder). 

        8.     Definitions.
Capitalized terms used but not otherwise defined in this Certificate of Designation shall have the meaning given to such terms
in the Series A Purchase Agreement. The following terms shall have the following meanings for purposes of this Certificate of Designation: 

        "Accreted Value" means, with respect to one share of Series A Preferred Stock, $22.50, plus the amount of any dividends added to
such Accreted Value in accordance with Section 2, minus the amount of any dividends included in Accreted Value that are subsequently
declared and paid (subject 

10

 

to
equitable adjustments by the Board acting in good faith to reflect stock splits of shares of Series A Preferred Stock, stock dividends in respect of shares of Series A Preferred
Stock, stock combinations of shares of Series A Preferred Stock, recapitalizations and like occurrences). 

        "Board" means the Board of Directors of the Corporation. 

        "Business Day" is defined in the Series A Purchase Agreement. 

        "Closing Date" is defined in the Series A Purchase Agreement. 

        "Common" means the Corporation's Common Stock, $0.001 par value per share. 

        "Conversion Price" means, with respect to each share of Series A Preferred Stock, initially $2.25 for such share, subject to
adjustment from time to time in accordance with Section 5(b). 

        "Dividend Payment Date" is defined in Section 2(b). 

        "Dividend Period" is defined in Section 2(b). 

        "EBITDA" means earnings before interest, taxes, depreciation and amortization expenses, in each case calculated in accordance with GAAP. 

        "Fair Market Value" means fair market value as determined in good faith by the Board. Any securities shall be valued as follows:
(i) securities not subject to investment letter or other similar restrictions on free marketability: 

        (A)  if
traded on a securities exchange or The Nasdaq Stock Market, the value shall be based on a formula approved in good faith by the Board and derived from the closing
prices of the securities on such exchange or The Nasdaq Stock Market over a specified time period; 

        (B)  if
actively traded over-the-counter, the value shall be based on a formula approved in good faith by the Board and derived from the closing
prices of the securities on such exchange or The Nasdaq Stock Market over a specified time period; and 

        (C)  if
there is no active public market, the value shall be the fair market value thereof, as determined in good faith by the Board; 

and
(ii) the method of valuation of securities subject to investment letter or other restrictions on free marketability (other than restrictions arising solely by virtue of a stockholder's
status as an affiliate or former affiliate) shall be to make an appropriate discount from the market value determined as above in clause (i) to reflect the approximate fair market value
thereof, as determined in good faith by the Board. 

        "Fundamental Change" means (i) any sale or transfer of all or substantially all of the assets of the Corporation in any transaction
or series of transactions or (ii) any merger or consolidation to which the Corporation is a party, except for a merger in which (a) the Corporation is the surviving corporation,
(b) the terms, rights and preferences of the Series A Preferred Stock are not adversely affected, (c) the Common is not converted into or exchanged for cash, securities or other
property, and (d) after giving effect to such merger, the holders of the Corporation's outstanding capital stock immediately prior to the merger shall continue to own the Corporation's
outstanding capital stock possessing a majority of the voting power of the Corporation and the voting power (under ordinary circumstances) to elect a majority of the Board. 

        "GAAP" is defined in the Series A Purchase Agreement. 

        "Indebtedness" means (i) all obligations for borrowed money or in respect of loans or advances; (ii) all obligations
evidenced by bonds, debentures, notes or other similar instruments; (iii) all obligations in respect of letters of credit, whether or not drawn; (iv) any Indebtedness of a third Person 

11

 

that
is guaranteed by the Corporation; or (v) any obligations under capitalized leases with respect to which the Corporation is liable. 

        "Investor" means RAM Trading, Ltd., a Cayman Islands exempted company. 

        "Junior Securities" means any of the Corporation's equity securities (whether or not currently authorized or outstanding) which by its
terms is junior to the Series A Preferred Stock (including, without limitation, the Common). 

        "Liens" is defined in the Series A Purchase Agreement. 

        "Liquidation Value" is defined in Section 4(a)(i). 

        "Make-Whole Redemption Price" is defined in Section 4(c). 

        "Mandatory Conversion" is defined in Section 5(c). 

        "Market Price" is defined in the Series A Purchase Agreement. 

        "Material Adverse Effect" is defined in the Series A Purchase Agreement. 

        "Optional Redemption Date" is defined in Section 6(a). 

        "Organic Change" is defined in Section 5(b)(ii). 

        "Original Issuance Date" means, with respect to any share of Series A Preferred Stock, the date on which the Corporation initially
issues such share of Series A Preferred Stock, regardless of the number of times a transfer of such share is made on the stock records maintained by or for the Corporation and regardless of the
number of certificates which may be issued to evidence such share. 

        "Original Issue Price" means $22.50 (subject to equitable adjustments by the Board acting in good faith to reflect stock splits of shares
of Series A Preferred Stock, stock dividends in respect of shares of Series A Preferred Stock, stock combinations of shares of Series A Preferred Stock, recapitalizations and like
occurrences). 

        "Permitted Acquisition" means an acquisition by the Company of another business entity with respect to which the pro
forma financial statements of the Company prepared in good faith by the Company's management reflecting such acquisition, which are submitted to the Board in connection with its
approval of such acquisition, demonstrate that such acquisition will not result in an overall decrease in the per share EBITDA of the Company over the four (4) fiscal quarters of the Company
beginning with the second full fiscal quarter following the consummation of such acquisition. For purposes of Section 6(c)(ii) of this Certificate of Designation,
shares of Common issued by the Company as consideration in connection with a Permitted Acquisition shall be deemed issued at a price equal to the Market Price on the Business Day immediately preceding
the day on which the definitive agreement for such acquisition is executed. 

        "Permitted Liens" is defined in the Series A Purchase Agreement. 

        "Person" means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a
joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. 

        "Redemption Notice" is defined in Section 6(a). 

        "Redemption Price" is defined in Section 6(a). 

        "Series A Purchase Agreement" means the Series A Preferred Stock Purchase Agreement, dated as of October 29, 2003,
between the Corporation and the Investor. 

12

 

        "Significant Event" means (i) a liquidation, dissolution or winding up of the Corporation, voluntary or otherwise, or (ii) a
Fundamental Change. 

        "Supermajority Preferred Holders" is defined in Section 3(b). 

        "Warrant" is defined in the Series A Purchase Agreement. 

13

 

        IN
WITNESS WHEREOF, Genaissance Pharmaceuticals, Inc. has caused this Certificate to be signed by Kevin L. Rakin, its President, on this 29th day of October, 2003. 

	 	 	Genaissance Pharmaceuticals, Inc.
	

 	
 	

By:	
 	

/s/  KEVIN L. RAKIN      
 Kevin L. Rakin, President

14

   AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

GENAISSANCE PHARMACEUTICALS, INC.  

        I, Gualberto Ruano, President of Genaissance Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law
of the State of Delaware, do hereby certify as follows: 

        A.    The
original Certificate of Incorporation of Genaissance Pharmaceuticals, Inc. (the "Corporation") was filed in the Office of the Secretary of State of the State
of Delaware on February 24, 1992 under the name "BIOS Laboratories, Inc." and was amended by: (i) Certificates of Amendment on August 29, 1994; March 18, 1997;
August 13, 1997; December 22, 1997; August 24, 1998; February 17, 2000; March 8, 2000; March 10, 2000; and July 25, 2000; (ii) a Certificate of
Designations on December 22, 1997, which was amended on August 24, 1998, February 17, 2000, March 10, 2000, July 25, 2000 and July 28, 2000; (iii) a
Certificate of Designations on August 24, 1998 which was amended on February 17, 2000, July 25, 2000 and July 28, 2000; (iv) a Certificate of Designations on
February 17, 2000 which was amended on March 8, 2000, March 10, 2000, July 25, 2000 and July 28, 2000; and (v) a Certificate of Designations on
March 10, 2000, which was amended on July 25, 2000 and July 28, 2000. 

        B.    In
the manner prescribed by Sections 242 and 245 of the General Corporation Law of the State of Delaware, this Amended and Restated Certificate of Incorporation was duly
adopted by the Board of Directors and stockholders of the Company. 

        C.    The
text of the Certificate of Incorporation of the Company is further amended and restated to read in full as follows: 

        FIRST:
The name of the Corporation is Genaissance Pharmaceuticals, Inc. 

        SECOND:
The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, in the City of Wilmington, New Castle County, Delaware. The name of its
registered agent at such address is The Corporation Trust Company. 

        THIRD:
The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware. 

        FOURTH:
The Corporation shall be authorized to issue sixty-one million (61,000,000) shares of capital stock, which shall be divided into fifty-eight million (58,000,000)
shares of Common Stock, par value $0.001 per share (the "Common Stock"), two million (2,000,000) shares of non-voting common stock, par value $0.001 per share (the "Non-Voting
Common Stock") and one million (1,000,000) shares of Preferred Stock, par value $0.001 per share (the "Preferred Stock"). 

        The
following is a statement of the designations, preferences, voting powers, qualifications, special or relative rights and privileges in respect of the authorized capital stock of the
Corporation. 

PREFERRED STOCK  

        The Board of Directors is authorized, subject to limitations prescribed by law and the provisions of this Article FOURTH, to provide by resolution for the
issuance of the shares of Preferred Stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware, to establish from time to time the number of
shares to be included in each such series, and to fix the designations, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof. 

15

 

        The
authority of the Board with respect to each series shall include, but shall not be limited to, determination of the following: 

	(a)
	The
number of shares constituting that series and the distinctive designation of that series;

	(b)
	The
dividend rate, if any, on the shares of that series, whether dividends shall be cumulative, and if so, from which date or dates, and the relative rights of priority, if any, of
payment of dividends on shares of the series;

	(c)
	Whether
that series shall have voting rights, in addition to the voting rights provided by law, and, if so, the terms of such voting rights;

	(d)
	Whether
that series shall have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for adjustment of the conversion rate in such events
as the Board of Directors shall determine;

	(e)
	Whether
or not the shares of that series shall be redeemable, and if so, the terms and conditions of such redemption, including the date or dates upon or after which they shall be
redeemable, and the amount per share payable in case of redemption, which amount may vary under different conditions and at different redemption dates;

	(f)
	Whether
that series shall have a sinking fund for the redemption or purchase of shares of that series, and if so, the terms and amount of such sinking fund;

	(g)
	The
rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the Corporation, and the relative rights of priority, if
any, of payment of shares of that series;

	(h)
	Any
other relative rights, preferences and limitations of that series. 

COMMON STOCK AND NON-VOTING COMMON STOCK  

        The Common Stock and the Non-Voting Common Stock are subject to the rights and preferences of the Preferred Stock as hereinbefore set forth or
authorized. 

        The
Common Stock and the Non-Voting Common Stock shall be identical in all respects and shall have equal rights and privileges, except as otherwise expressly provided herein.
The relative powers, preferences, rights, qualifications, limitation and restrictions of the shares of the Common Stock and the Non-Voting Common Stock are as follows: 

        1.     VOTING.
Subject to the provisions of any applicable law or of the by-laws of the Corporation, as from time to time amended, with
respect to the fixing of a record date for the determination of stockholders entitled to vote, and except as otherwise provided herein or by law or by the resolution or resolutions providing for the
issue of any series of Preferred Stock, the holders of outstanding shares of Common Stock shall have exclusive voting rights for the election of directors and for all other purposes, each holder of
record of shares of Common Stock being entitled to one vote for each share of Common Stock standing in his name on the books of the Corporation. Except as provided under the Delaware General
Corporation Law, the holders of the Non-Voting Common Stock are not entitled to vote. 

        2.     DIVIDENDS.
Subject to the rights of any one or more series of Preferred Stock, the holders of Common Stock and Non-Voting Common
Stock shall be entitled to receive such dividends from time to time as may be declared by the Board of Directors out of any funds of the Corporation legally available for the payment of such
dividends. 

        3.     LIQUIDATION.
In the event of the liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, after payment
shall have been made to the holders of 

16

 

the
Preferred Stock of the full amount to which they are entitled, the holders of Common Stock and Non-Voting Common Stock shall be entitled to share ratably according to the number of
shares of Common Stock and Non-Voting Common Stock held by them in all remaining assets of the Corporation available for distribution to its stockholders. 

        4.     CONVERSION
OF NON-VOTING COMMON STOCK. 

        (a)   OPTIONAL
CONVERSION. Subject to applicable banking regulations, each share of Non-Voting Common Stock shall be convertible, at
the option of the holder thereof, at any time and from time to time, into shares of Common Stock at the rate (subject to equitable adjustment as may be necessary to account for stock splits, stock
dividends or any reorganization, combination of shares or similar capital adjustment) of one share of Common Stock for each share of Non-Voting Common Stock by surrendering the certificate
or certificates for such shares of Non-Voting Common Stock, together with written notice that such holder elects to convert all or any portion of the shares of Non-Voting
Common Stock represented by such certificate or certificates and any other documents required by the transfer agent or the Corporation, to the office of the transfer agent (which shall be the
principal office of the Corporation if it serves as its own transfer agent). Such notice shall state the names of the nominees, if any, in which such holder wishes the certificate or certificates for
the shares of Common Stock to be issued. The date of receipt of such certificates and notice by the transfer agent (or by the Corporation if it serves as its own transfer agent) shall be the
conversion date. The Corporation shall, as soon as practicable after such conversion date, issue and deliver at such office to such holder of Non-Voting Common Stock, or to its nominees, a
certificate or certificates for the
number of shares of Common Stock to which such holder shall be entitled, together with cash in lieu of any fraction of a share. 

        (b)   RESERVING
COMMON STOCK. The Corporation shall reserve and keep available out of its authorized but unissued Common Stock such number of
shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Non-Voting Common Stock. 

ISSUANCE  

        Subject to the provisions of this Amended and Restated Certificate of Incorporation and except as otherwise provided by law, the shares of stock of the
Corporation, regardless of class, may be issued for such consideration and for such corporate purposes as the Board of Directors may from time to time determine. 

        FIFTH:
The following provisions are inserted for the management of the business and for the conduct of the affairs of the Corporation: 

        1.     The
directors shall be divided into three classes, as nearly equal in number as the then total number of directors constituting the entire Board permits, with the term of
office of one class expiring each year. The initial Class I directors elected by the stockholders of the Corporation shall hold office for a term expiring at the 2001 annual meeting of
stockholders; the initial Class II directors elected by the stockholders of the Corporation shall hold office for a term expiring at the 2002 annual meeting of stockholders; and the initial
Class III directors elected by the stockholders of the Corporation shall hold office for a term expiring at the 2003 annual meeting of stockholders. At each such annual meeting of stockholders
and at each annual meeting thereafter, successors to the class of directors whose term expires at that meeting shall be elected for a term expiring at the third annual meeting following their election
and until their successors shall be elected and qualified, subject to prior death, resignation, retirement or removal. If the number of directors is changed, any increase or decrease shall be
apportioned among the classes so as to maintain the number of directors in each class as nearly equal as possible, but in no event will a decrease in the number of directors shorten the term of any
incumbent director. Notwithstanding the foregoing, and except as otherwise required by law, whenever 

17

 

the
holders of any one or more series of Preferred Stock shall have the right, voting separately as a class, to elect one or more directors of the Corporation, the election, terms of office and other
features of such directorships shall be governed by the terms of the vote establishing such series, and such directors so elected shall not be divided into classes pursuant to this Article FIFTH
unless expressly provided by such terms. This Section 1 of Article FIFTH may not be amended, revised or revoked, in whole or in part, except by the affirmative vote of the holders of 80% of the
voting power of the shares of all classes of stock of the Corporation entitled to vote for the election of directors, considered for the purposes of this Article FIFTH as one class of stock. 

        2.     Each
director chosen to fill a vacancy in the Board of Directors shall be elected to complete the term of office of the director who is being succeeded. In the case of
any election of a new director to fill a directorship created by an enlargement of the Board, the Board shall in such election assign the class of directors to which such additional director is being
elected, and each director so elected shall hold office for the same term as the other members of the class to which the director is assigned. 

        3.     Except
as otherwise determined by the Board of Directors in establishing a series of Preferred Stock as to directors elected by holders of such series, at any special
meeting of the stockholders called at least in part for the purpose, any director or directors may, by the affirmative vote of the holders of at least a majority of the stock entitled to vote for the
election of directors, be removed from office for cause. The provisions of this subsection shall be the exclusive method for the removal of directors. This Section 3 of Article FIFTH may not be
amended, revised or revoked, in whole or in part, except by the affirmative vote of the holders of 80% of the voting power of the shares of all classes of stock of the Corporation entitled to vote for
the election of directors, considered for the purposes of this Article FIFTH as one class of stock. 

        4.     Elections
of directors need not be by ballot. 

        5.     The
Board of Directors of the Corporation is expressly authorized to adopt, amend or repeal the by-laws of the Corporation. 

        6.     A
director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director,
except for liability (i) for any breach of the director's duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or that involve intentional
misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware General Corporation Law, or (iv) for any transaction from which the director derived an improper
personal benefit. If the Delaware General Corporation Law is amended after approval by the stockholders of this Article FIFTH to authorize corporate action further eliminating or limiting the personal
liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended from
time to time. 

        Any
repeal or modification of this Section 6 of Article FIFTH shall not increase the personal liability of any director of this Corporation for any act or occurrence taking place
before such repeal or modification, nor otherwise adversely affect any right or protection of a director of the Corporation existing at the time of such repeal or modification. 

        7.     Meetings
of stockholders may be held anywhere within or without the State of Delaware. The books of the Corporation may be kept outside the State of Delaware at such
place or places as may be designated from time to time by the Board of Directors or in the by-laws of the Corporation. 

        SIXTH:
No action required to be taken or that may be taken at any annual or special meeting of stockholders of the Corporation may be taken by written consent without a meeting, and the
power of stockholders to consent in writing, without a meeting, to the taking of any action is specifically denied. 

18

 

        This
Article SIXTH may not be amended, revised or revoked, in whole or in part, except by the affirmative vote of the holders of 80% of the voting power of the shares of all classes of
stock of the Corporation entitled to vote for the election of directors, considered for the purposes of this Article SIXTH as one class of stock. 

        SEVENTH:
The Corporation reserves the right to amend, alter, change or repeal any provisions contained in this Amended and Restated Certificate of Incorporation in the manner now or
hereafter prescribed by statute, and all rights conferred upon stockholders are granted subject to this reservation. 

19

 

        IN
WITNESS WHEREOF, the undersigned has duly executed this Amended and Restated Certificate of Incorporation in the name and on behalf of Genaissance Pharmaceuticals, Inc. on the
7th day of August, 2000 and the statements contained herein are affirmed as true under penalties of perjury. 

	 	 	/s/  GUALBERTO RUANO      
 Gualberto Ruano

President and Chief Executive Officer

20

QuickLinks

Exhibit 4.1QuickLinks
 -- Click here to rapidly navigate through this document

  

	CONFIDENTIAL	 	REDACTED VERSION

        [***]
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS. 

 
 

TERM SHEET    
    

        This binding Term Sheet sets forth the agreement of Chiron Corporation ("Chiron"), on the one hand, and F. Hoffmann-La Roche Ltd. and Roche
Molecular Systems, Inc. (collectively, "Roche"), on the other, with respect to the settlement of their current arbitration relating to royalties ("Arbitration"), through amendment of the HIV
Probe License Agreement by and between the parties effective as of October 10, 2000 ("Clinical Diagnostics Agreement") and the Blood Screening HIV Probe License Agreement by and between the
parties effective as of January 1, 2001 ("Blood Screening Agreement," collectively with the Clinical Diagnostics Agreement, the "Agreements"). Terms not defined in this Term Sheet have the
meanings given to them in the applicable Agreement. This Term Sheet shall become effective as of September 3, 2004. 

	1.
	Definitions:

	a.
	"Additional
Chiron Patents" means Valid Claims Directed to HIV that cover the manufacture, use, sale, offer for sale, or importation of a Product that are contained within all patents
and applications, including future patents or applications, that are based on inventions conceived by CHIRON or its Affiliates on or before  [***] but are not CHIRON Licensed Patents, and are owned by
Chiron or its Affiliates as of  [***].

	b.
	Excluded
Party" means [***] and any of its affiliates and any successors or assigns to any of their business relating to the CHIRON Licensed Patents, and any
third person that is licensed, now or in the future, under the CHIRON Licensed Patents; in each case, that is acquired by Roche or which acquires Roche after [***], but
excluding [***].

	c.
	"Limiting
Event," with respect to an Agreement, means (i) the permissible assignment of such Agreement to any Excluded Party, or (ii) any Roche Affiliate that is involved
in the businesses to which such Agreement relates becoming directly or indirectly controlled by an Excluded Party (control being defined as set forth in Section 1.2 of such Agreement).

	d.
	"Option
Products" means Products that are used by or sold to an End User under circumstances and in jurisdictions, such that in the absence of the license granted pursuant to
Section 2.5 of the Clinical Diagnostics Agreement, such use or sale would constitute an infringement of a Valid Claim of the CHIRON Future HIV Sequence Patent Rights.

	e.
	"Qualified
Product" means Licensed Products sold by Roche or the Roche portion of the business of an Excluded Party that, prior to a Limiting Event, Roche had offered for commercial
sale or commercially sold or in respect of which Roche had filed with the Food and Drug Administration a Section 510(k) Premarket Notification or a Section 515 Premarket Approval and any
improvements of such Licensed Products or modifications thereto after the Limiting Event.

	f.
	"Roche
Products" means all assays sold by Roche for the detection, quantitation, genotyping or other analyses of nucleic acid sequences Directed to HIV ("Purpose") for use in in vitro
diagnostics and/or Blood Screening, including without limitation the following products of Roche: Amplicor HIV-1 test, v. 1.0; Amplicor HIV-1 Monitor test, v. 1.0; Amplicor
HIV-1 Monitor test, v. 1.5; COBAS Amplicor HIV-1 Monitor test, v. 1.5; Ampliscreen HIV-1 test, v. 1.5; and COBAS Ampliscreen HIV-1 test, v. 1.5; and all
versions of and successors and substitutes therefor. 

1

 

	g.
	"Territory"
means the United States, its territories and possessions, Puerto Rico, Canada, and Mexico.

	2.
	The
parties hereby irrevocably stipulate as follows:

	a.
	The
CHIRON Licensed Patents in the Territory are valid and enforceable;

	b.
	The
making, use, offer for sale, sale, or importation of any Roche Product in the Territory, where a CHIRON Licensed Patent has issued and prior to the expiration of such CHIRON
Licensed Patent, would, in the absence of the licenses granted in the Agreements, as applicable, constitute infringement of one or more claims of such CHIRON Licensed Patent;

	c.
	The
license fees and royalty payments set forth in the Agreements are due to Chiron for sales of the Roche Products in the Territory;

	d.
	Roche
releases any claims it asserted in the Arbitration (or arising out of the same facts and circumstances as the claims it asserted in the Arbitration) that are contrary to the
foregoing subsections a, b, and c; and

	e.
	Chiron
and Roche Molecular Systems, Inc., with the express authorization of F. Hoffmann-La Roche Ltd., shall, immediately upon approval of this Term Sheet by
Chiron's Board of Directors, execute the stipulation appended hereto as Exhibit A ("Stipulation") and request that the arbitrator in the Arbitration enter an award in the Arbitration consistent
with such stipulation. Roche Molecular Systems, Inc. shall thereafter promptly exercise commercially reasonable efforts to support any steps Chiron may undertake to have such stipulated
arbitration award promptly confirmed by a court of competent jurisdiction selected by Chiron.

	f.
	Nothing
in this Term Sheet or the Stipulation shall apply to claims of the CHIRON Licensed Patents that are not directed to the Purpose; by way of example but not by way of limitation,
Valid Claims of CHIRON Licensed Patents directed to immunoassays, antigens, antibodies, and/or proteins are expressly excluded from the terms of this Term Sheet and the Stipulation, including, without
limitation, Sections 2(a) and 2(b), subject to the final sentence of Section 8(a).

	3.
	Royalty
Provisions. The royalty provisions of the Agreements are amended as follows:

	a.
	Clinical
Diagnostics Agreement

	i.
	All
monies already paid to Chiron pursuant to the Clinical Diagnostics Agreement shall be retained by Chiron and are non-refundable, including, without
limitation, the Ten Million United States Dollars (USD$10,000,000) U.S. Licensing Fee, any royalties for sales made prior to January 1, 2001, and any royalties for sales made thereafter but
prior to [***].

	ii.
	For
sales in Region I during the period from [***] through  [***], Earned Royalties, as defined in Exhibit A, will be modified as follows:

	x.
	The
[***] percent ([***]%)
rate set forth in Paragraph 3 of Exhibit A shall be [***] adjusted to  [***] percent ([***]%);

	y.
	the
Minimum Amount/Test set forth in Paragraph 4 of Exhibit A for the HIV Qualitative Assay field shall be
US$[***], rather than US$[***]; and

	z.
	the
Minimum Amount/Test set forth in Paragraph 4 of Exhibit A for the HIV Quantitative Assay field shall be
US$[***], rather than US$[***].

	iii.
	On
or within 10 days following January 1, 2005, Roche shall pay Chiron Fifty-Two Million United States Dollars (USD52,000,000) in cumulative
Earned Royalties for sales made in 

2

 

Region I
after January 1, 2005 and continuing through the life of the applicable CHIRON Licensed Patent(s). Subject to Section 5, such payment shall be nonrefundable. Upon this
Term Sheet becoming binding on all of the parties pursuant to Section 10, the definition of "CHIRON Licensed Patents" in the Clinical Diagnostics Agreement shall be expanded to include the
"Additional Chiron Patents." Subject to Sections 5 and 6, upon the payment of such amount, nothing further shall be due to Chiron from Roche in consideration of the licenses granted pursuant to
Sections 2.1 and 2.3 of the Clinical Diagnostics Agreement for sales in Region I of CHIRON Licensed Products made after January 1, 2005. 

	iv.
	With
respect to CHIRON Future HIV Sequence Patent Rights acquired by Chiron after [***] but prior
to ("[***]"), pursuant to Section 2.5 of the Clinical Diagnostics Agreement, Chiron agrees to grant such rights to Roche
on the following payment terms:

	w.
	If
Chiron may license such rights to Roche without incurring any incremental payment obligation to any person arising from the granting or exercise by Roche of such
license, Roche's payment obligation set forth in Section 3(a)(iii) shall be [***]with respect to sales by Roche
and Roche Affiliates of Option Products in Region I through the [***], and [***]  shall be due to Chiron from Roche in consideration of such license for
sales in Region I of Option Products through the  [***]. For sales in Regions other than Region I and for sales in any Region after the  [***], Roche's
payment obligations for such license shall be determined in accordance with subsection y.

	x.
	If
Chiron would incur any incremental payment obligation to any person arising from the granting or exercise by Roche of such license, Roche  [***] and [***]
shall be due to Chiron from Roche in
consideration of such license for sales in Region I of Option Products through the [***]. For sales in Regions other than Region
I and for sales in any Region after the [***], Roche's payment obligations for such license shall be determined in accordance
with subsection y..

	y.
	Roche's
payment obligations for sales of Option Products not established by subsections w and × shall be  [***] and resolved, if necessary, through the ADR process in accordance with
Article 10 of the Clinical Diagnostics
Agreement to determine the terms that are commercially reasonable.

	z.
	The
terms of the Clinical Diagnostic Agreement shall be modified as necessary to make such Agreement (i) no less protective of Chiron with respect to licenses
granted pursuant to Section 2.5 than such Agreement is with respect to the licenses set forth in Sections 2.1 and 2.3, including, by way of example but not limitation, with respect to payment,
reporting, and audit rights; and (ii) consistent with any agreement under which Chiron acquires any CHIRON Future HIV Sequence Patent Rights after  [***] but prior to the [***], including, by way of
example but not limitation, with respect to payment, reporting, and audit rights.

	b.
	Blood
Screening Agreement

	i.
	All
monies already paid to Chiron pursuant to the Blood Screening Agreement shall be retained by Chiron and are non-refundable, including, without limitation,
any royalties for sales made prior to [***].

	ii.
	For
sales in Region II during the period from [***] through  [***], the Earned Royalty Amounts under Exhibit A will be modified as follows:

	x.
	the
applicable Earned Royalty Amount for Blood Screening will be $[***]; and 

3

 

	y.
	the
applicable Earned Royalty Amount for Plasma Fractionation will be $[***].

	iii.
	On
or within 10 days following January 1, 2005, Roche shall pay Chiron Twenty-Six Million United States Dollars (USD26,000,000) in cumulative
Earned Royalties for sales made in Region II after January 1, 2005 and continuing through the life of the applicable CHIRON Licensed Patent(s). Subject to Section 5, such payment
shall be nonrefundable. Upon this Term Sheet becoming binding on all of the parties pursuant to Section 10, the definition of "CHIRON Licensed Patents" in the Blood Screening Agreement shall be
expanded to include the "Additional Chiron Patents." Subject to Sections 5 and 6, upon the payment of such amount, nothing further shall be due to Chiron from Roche in consideration of the
licenses granted pursuant to Section 2.1 of the Blood Screening Agreement for sales in Region II of CHIRON Licensed Products made after January 1, 2005.

	4.
	For
purposes of this Term Sheet, a Product shall be deemed to have been sold in the Region in which the Product is used by an End User resulting in the Product's consumption,
operation, destruction, or loss of activity.

	5.
	a.    At
any time on or after January 25, 2005, Roche may notify Chiron that it desires a partial refund of the payments made pursuant to Sections 3(a)(iii) and
3(b)(iii). Roche's request shall be deemed to have been made on the Refund Request Date set forth in Exhibit C that immediately follows the effective date of such notice. Within
forty-five (45) days after such Refund Request Date, Chiron shall refund to Roche the Refund Amounts set forth on Exhibit C for each Agreement that correspond to such Refund
Request Date.

	b.
	As
of such Refund Request Date, the payments made by Roche pursuant to Section 3(a)(iii) shall no longer be deemed to be cumulative Earned Royalties for sales made in
Region I after January 1, 2005 under the Clinical Diagnostics Agreement. Under the Clinical Diagnostics Agreement, from such Refund Request Date through the Term of the Clinical Diagnostics
Agreement:

	i.
	the
Earned Royalty rate for sales of Licensed Products in the Territory shall be the Clinical Diagnostics Earned Royalty Rate set forth in Exhibit C that
corresponds to such Refund Request Date;

	ii.
	the
Minimum Amount/Test set forth in Paragraph 4 of Exhibit A for the HIV Qualitative Assay field shall be the Minimum Amount/Test for the HIV Qualitative
Assay field set forth in Exhibit C that corresponds to such Refund Request Date; and

	iii.
	the
Minimum Amount/Test set forth in Paragraph 4 of Exhibit A for the HIV Quantitative Assay field shall be the Minimum Amount/Test for the HIV
Quantitative Assay field set forth in Exhibit C that corresponds to such Refund Request Date.

	c.
	As
of such Refund Request Date, the payments made pursuant to Section 3(b)(iii) shall no longer be deemed to be cumulative Earned Royalties for sales made in Region II
after January 1, 2005 under the Blood Screening Agreement. Under the Blood Screening Agreement, from such Refund Request Date through the through the Term of the Blood Screening Agreement:

	i.
	the
applicable Earned Royalty Amount for Blood Screening shall be the Earned Royalty Amount for Blood Screening set forth in Exhibit C that corresponds to such
Refund Request Date; and

	ii.
	the
applicable Earned Royalty Amount for Plasma Fractionation shall be the Earned Royalty Amount for Plasma Fractionation set forth in Exhibit C that corresponds
to such Refund Request Date. 

4

 

	d.
	After
October 2, 2006, Roche shall no longer be entitled to any refund pursuant to this Section 5.

	6.
	Except
with respect to products as to which Earned Royalties will be paid at adjusted rates and amounts pursuant to Section 5 and Exhibit C and products coming within the
terms of Section 7, the most favored nations provisions of the Agreements shall be of no further force or effect, retrospectively, currently, or prospectively, with respect to Region I, in the
case of the Clinical Diagnostics Agreement, and Region II, in the case of the Blood Screening Agreement.

	7.
	a.    Except
as provided in Sections 7(b) and 7(c), the royalty provisions of the Agreements as amended by this Term Sheet will not benefit any Excluded Party (as defined
above) or apply to any products developed by or on behalf of any Excluded Party. Rather, to the extent any such person or product benefits from the licenses granted under the Agreements, the royalty
provisions set forth in the Agreements prior to their amendment by this Term Sheet shall apply.

	b.
	If
a Limiting Event should occur with respect to the Clinical Diagnostics Agreement, the royalty provisions of this Term Sheet, including, without limitation, the payments made
pursuant to Section 3(a)(iii):

	i.
	shall
apply in the twelve-month period following such Limiting Event with respect to, and only with respect to a volume of Qualified Products having an aggregate selling
price equal to [***] of such Qualified Products sold in the Territory by Roche during the Calendar Year immediately preceding
such Limiting Event plus [***] percent ([***]%), and

	ii.
	shall
apply in each of the successive twelve-month periods following such Limiting Event with respect to, and only with respect to a volume of Qualified Products having
an aggregate selling price equal to [***] plus [***]
percent ([***]%).

	c.
	If
a Limiting Event should occur with respect to the Blood Screening Agreement, the royalty provisions of this Term Sheet, including, without limitation, the payments made pursuant to
Section 3(b)(iii):

	i.
	shall
apply in the twelve-month period following such Limiting Event with respect to, and only with respect to a volume of Qualified Products having an aggregate selling
price equal to [***] of such Qualified Products sold in the Territory by Roche during the Calendar Year immediately preceding
such Limiting Event plus [***] percent ([***]%), and

	ii.
	shall
apply in each of the successive twelve-month periods following such Limiting Event with respect to, and only with respect to a volume of Qualified Products having
an aggregate selling price equal to [***] plus [***]  percent ([***]%).

	8.
	a.    Neither
Roche nor any of its Affiliates (each, a "Roche Party") shall initiate, bring, or otherwise challenge the validity or enforceability of, or seek to oppose the
issuance of or narrow the issued or applied for claims, scope, or duration of, any of the claims of a CHIRON Licensed Patent in the Territory, directed to the Purpose, including, without limitation,
any interferences, reexaminations, or other proceedings in the U.S. Patent and Trademark Office or any other office, administration, or agency in the Territory. In addition, no Roche Party shall
"support", as defined in Section 7.3(b) of the Clinical Diagnostics Agreement, any third person in initiating, bringing, or otherwise challenging the validity or enforceability of, or seeking
to oppose the issuance of or narrow the issued or applied for claims, scope, or duration of, any of the claims of a CHIRON Licensed Patent in the Territory, directed to the Purpose, including, without
limitation, any interferences, reexaminations, or other proceedings in the U.S. Patent and Trademark Office or any other office, administration, or agency in the Territory. Further, none of the Roche
Parties 

5

 

shall
challenge the validity or enforceability of any patent containing a claim within the CHIRON Licensed Patents in the Territory, or "support," as defined in Section 7.3(b) of the Clinical
Diagnostics Agreement, a challenge by a third party to the validity or enforceability of any such patent to the extent such challenge could invalidate or impair the enforceability of any claim
directed to the Purpose; provided, however, that nothing in this Term Sheet amends, derogates, or changes in any way the rights and obligations of Roche Diagnostics GmbH under the Cross License
Agreement on HIV (Immunoassays) between Roche Diagnostics GmbH, Dade Behring, Ortho Clinical Diagnostics, and Chiron dated November, 2002. 

	b.
	Roche
shall direct its counsel to convey all Subject Documents (as defined below) to Roche, except that each firm may maintain one archival copy of the Subject Documents (solely for
use in a manner not inconsistent with the purposes of this Section 8), and Roche shall confirm its receipt of the Subject Documents to Chiron. Roche shall use all commercially reasonable
efforts to prevent any Subject Documents from being used by, or for the benefit of, any third person and shall take all commercially reasonable steps to prohibit such use from occurring. "Subject
Documents" means any writing prepared for or in connection with representation of Roche, whether in paper, electronic, or other form, prepared in connection with the Arbitration or the facts and
circumstances relating thereto or relating to the validity or enforceability of the CHIRON Licensed Patents, including any and all pleadings, briefs, declarations, and other papers submitted in the
Arbitration, drafts thereof, deposition transcripts, summaries thereof, memoranda, attorney or consultant work product, and any writing containing any Designated Materials (as defined in the
Protective Order in the Arbitration) of Chiron or excerpts or analysis thereof. Notwithstanding anything provided in this Section 8 to the contrary, expressly recognizing that Stephen S.
Rabinowitz, Esq. and his present firm Fried, Frank, Harris, Shriver & Jacobson LLP (collectively "Fried Frank") have been and are representing Laboratory Corporation of America Holdings and its
affiliates in a civil action commenced by Chiron and pending in the United States District Court for the Central District of California Case No. 04 CV 1064 MRP (the "LabCorp Case"), nothing
done (in the past, present or future) by Fried Frank in or in connection with the LabCorp Case in contravention of written instructions from Roche following September 3, 2004 of which Chiron
has received notice shall be deemed to be a violation by Roche of this Section 8; provided that (i) Roche shall instruct Fried Frank not to make any use in the future of any Subject
Document Fried Frank prepared in the course of acting on behalf of Roche in the Roche/Chiron arbitration and to otherwise comply with this Section 8, and (ii) that Roche otherwise
complies with this Section 8.

	9.
	Each
party shall bear its own fees incurred in connection with the Arbitration and shall bear half the expenses of the arbitrator.

	10.
	By
executing this Term Sheet, each party agrees to be bound by its terms, subject in the case of Chiron to approval by the Chiron Board of Directors. It is the current intention of
the parties to execute definitive amendments to the Agreements that will supercede this Term Sheet, however, if such definitive amendments are not prepared and/or executed by the parties, this Term
Sheet will remain binding upon the parties. This Term Sheet (including the Stipulations in Exhibits A and B and the chart in Exhibit C hereto, which are incorporated herein by reference), the
Agreements, and the Settlement Agreement effective as of October 10, 2000 constitute the complete agreement between the parties and supersede all prior or contemporaneous agreements or
representations, written or oral, concerning the subject matter of this Term Sheet. No party shall rely on any oral or written representation other than as expressly set forth herein. This Term Sheet
and all matters arising out of or relating to this Term Sheet shall be interpreted and enforced under the laws of the State of New York. The provisions of Section 9 of the Settlement Agreement
effective as of October 10, 2000 shall apply to any dispute arising out of or relating to this Term Sheet. 

6

 
	11.
	Each
party may issue a press release disclosing the existence of this Term Sheet. The terms of this Term Sheet and the definitive agreements based on this Term Sheet ("Terms") will be
"Information" of both parties pursuant to Article 8 of the Clinical Diagnostics Agreement. Notwithstanding the foregoing, (i) the Terms shall be expressly subject to Section 8.4
of the Clinical Diagnostics Agreement and (ii) Chiron may disclose such Terms to [***] and  [***],
provided that the recipient of such disclosure has agreed to
confidentiality obligations applicable to the Terms no less restrictive than those contained in Article 8 of the Clinical Diagnostics Agreement.

	12.
	This
Section 12 shall be immediately binding on each party upon execution of this Term Sheet by all of Chiron, Roche Molecular Systems, Inc., and F.
Hoffmann-La Roche Ltd. At such time, each of Chiron and Roche Molecular Systems, Inc. shall execute the Renewed Stipulation Re Delayed Rendering of Award appended hereto as
Exhibit B and promptly submit such stipulation to the arbitrator in the Arbitration. 

AGREED
TO AND ACCEPTED BY: 

Chiron
Corporation 

	

By:	
 	

/s/  JEKENT      	
 	

 
	Date:	 	Sept. 3, 2004	 	 
	

AGREED TO AND ACCEPTED BY:
	

F. Hoffmann-La Roche Ltd.
	

By:	
 	

/s/  HEINO VON PRONDZYNSKI      	
 	

 
	 	 	/s/  ROBERT YATES      	 	 
	Date:	 	3 Sept 04	 	 
	

AGREED TO AND ACCEPTED BY:
	

Roche Molecular Systems, Inc.
	

By:	
 	

/s/  H. DREISMANN      	
 	

 
	Date:	 	September 3, 2004	 	 

7

  

 
 

EXHIBIT A
  before The honorable
  Charles B. Renfrew, arbitrator    
    

	

 IN THE MATTER OF THE ARBITRATION

BETWEEN

CHIRON CORPORATION,

Claimant

AND

ROCHE MOLECULAR SYSTEMS, INC.,

Respondent	

 	

STIPULATED ARBITRATION AWARD

Stipulation  

Chiron
Corporation and Roche Molecular Systems, Inc., on behalf of themselves and their affiliates, hereby irrevocably stipulate as follows: 

	1.
	"Agreements"
means the HIV Probe License Agreement by and between the parties effective as of October 10, 2000 and the Blood Screening HIV Probe License Agreement by and between
the parties effective as of January 1, 2001;

	2.
	"Blood
Screening" means the commercial use of products that detect nucleic acid sequence(s) for: (a) the screening of blood, plasma or blood components intended for transfusion
or for use in blood products (e.g., without limitation, immunoglobulins); or (b) confirmatory or supplemental testing of the same samples otherwise screened for purposes described in (a);

	3.
	"Directed
to HIV" means that the claim or technology in question is directed to methods, compositions, reagents or kits specifically for use in nucleic acid-based
diagnostic assays for the detection of HIV nucleic acid sequence(s), or specifically for use in the manufacture of any compositions or reagents for use in, or manufacture of nucleic
acid-based diagnostic assays for detection of HIV nucleic acid sequence(s) (excluding, for example, polymerase chain reaction claims and technology and other methods for detection of
nucleic acid sequence(s) generally which involve nucleic acid amplification). The terminology "specifically for use" as used in this definition, is intended to exclude inventions suitable for use with
viruses or analytes other than HIV (including by way of example and not by way of limitation, inventions relating to polymerase chain reaction, or assay formats, improved expression systems,
detectable labels, instrumentation, packaging and the like), which shall not be considered "specifically for use" in HIV detection as contemplated by this definition and shall therefore not be
considered as "Directed to HIV" hereunder;

	4.
	"HIV"
means any viral isolate of the human immunodeficiency virus classified as HIV by the International Committee on the Taxonomy of Viruses (or any body that replaces such Committee)
or any subtype of such isolate and further includes any isolate that is at least forty percent (40%) homologous to any such isolate and of the same genomic type and substantially the same genomic
organization, any isolate that has a genome that either hybridizes to or is substantially identical to any such isolate or its compliment, and any defective or modified form of any of the above
isolates;

	5.
	"Patent"
means U.S. Patent No. 6,531,276 B1;

	6.
	"Roche
Products" means all assays sold by Roche Molecular Systems, Inc. for the detection, quantitation, genotyping or other analyses of nucleic acid sequences Directed to HIV
for use in in vitro diagnostics and/or Blood Screening, including without limitation the following products of Roche Molecular Systems, Inc.: Amplicor HIV-1 test, v. 1.0; Amplicor
HIV-1 Monitor test, v. 1.0; 

8

 

Amplicor
HIV-1 Monitor test, v. 1.5; COBAS Amplicor HIV-1 Monitor test, v. 1.5; Ampliscreen HIV-1 test, v. 1.5; and COBAS Ampliscreen HIV-1 test, v.
1.5; and all versions and successors and substitutes therefor; 

	7.
	The
Patent is valid and enforceable;

	8.
	The
making, use, offer for sale, sale, or importation into the United States of any Roche Product would, in the absence of the licenses granted in the Agreements, as applicable,
constitute infringement of one or more claims of the Patent;

	9.
	The
license fees and royalty payments set forth in the Agreements are due to Chiron for sales of the Roche Products in the United States;

	10.
	Roche
Molecular Systems, Inc., on behalf of itself and its affiliates, releases any claims it asserted in the Arbitration (or arising out of the same facts and circumstances as
the claims it asserted in the Arbitration) that are contrary to the foregoing Sections 7, 8, and 9; and

	11.
	The
parties hereby request that the Arbitrator enter an award in the above-captioned Arbitration consistent with the forgoing stipulation. Roche Molecular Systems, Inc. shall
thereafter promptly exercise commercially reasonable efforts to support any steps Chiron may undertake to have such stipulated arbitration award promptly confirmed by a court of competent jurisdiction
selected by Chiron. 

	

Date: August    , 2004	
 	

Agreed:	

 
	 	 	 	

	

 	
 	

Stephen S. Rabinowitz

FRIED, FRANK, HARRIS, SHRIVER & JACOBSON LLP
	

 	
 	

Charles B. Cohler

PAUL, HASTINGS, JANOFSKY & WALKER LLP
	

 	
 	

Attorneys for Roche Molecular Systems, Inc.
	

Date: August    , 2004	
 	

Agreed:	

 
	 	 	 	

	

 	
 	

Rachel Krevans

Mathew I. Kreeger

Wesley E. Overson

Lawrence B. Berroya

Peter P. Meringolo

MORRISON & FOERSTER LLP
	

 	
 	

Attorneys for Chiron Corporation

9

 

IT
IS SO ORDERED. 

	

By:	

 Hon. Charles B. Renfrew, Arbitrator	
 	

 
	

Date:	

	
 	

 

10

  

 
 

EXHIBIT B
  before The honorable
  Charles B. Renfrew, arbitrator    
    

	

 IN THE MATTER OF THE ARBITRATION

BETWEEN

CHIRON CORPORATION,

Claimant

AND

ROCHE MOLECULAR SYSTEMS, INC.,

Respondent	

 	

RENEWED STIPULATED RE DELAYED RENDERING OF AWARD

Stipulation  

Chiron
Corporation and Roche Molecular Systems, Inc., on behalf of themselves and their affiliates, jointly agree and stipulate as follows: 

Notwithstanding
Section 9(d)(12) of Settlement Agreement by and between the parties effective as of October 10, 2000, which requires that the Arbitrator render an award in this
Arbitration together with a decision on the award in writing ("Award") within seven calendar days following the submission of post-hearing briefs, the parties jointly request that the
Arbitrator not render the Award prior to September 14, 2004, at 4:00 p.m. 

	

Date: August    , 2004	
 	

Agreed:	

 
	 	 	 	

	

 	
 	

Stephen S. Rabinowitz

FRIED, FRANK, HARRIS, SHRIVER & JACOBSON LLP
	

 	
 	

Charles B. Cohler

PAUL, HASTINGS, JANOFSKY & WALKER LLP
	

 	
 	

Attorneys for Roche Molecular Systems, Inc.
	

Date: August    , 2004	
 	

Agreed:	

 
	 	 	 	

	

 	
 	

Rachel Krevans

Mathew I. Kreeger

Wesley E. Overson

Lawrence B. Berroya

Peter P. Meringolo

MORRISON & FOERSTER LLP
	

 	
 	

Attorneys for Chiron Corporation

11

  

 
 

EXHIBIT C
  
    REFUND SCHEDULE AND ADJUSTED ROYALTY RATES    
    

	Refund

Request

Date
	 	Refund

Amount:

Clinical

Diagnostics

(MM)
	 	Refund

Amount:

Blood

Screening

(MM)
	 	Clinical

Diagnostics

Earned

Royalty

Rate
	 	Minimum

Amount/Test:

HIV Qualitative

Assay
	 	Minimum

Amount/Test:

HIV Quantitative

Assay
	 	Earned

Royalty

Amount:

Blood

Screening
	 	Earned

Royalty

Amount:

Plasma

Fractation

	2/1/05	 	$	[***]	 	$	[***]	 	[***]	%	$	[***]	 	$	[***]	 	$	[***]	 	$	[***]
	3/31/05	 	$	[***]	 	$	[***]	 	[***]	%	$	[***]	 	$	[***]	 	$	[***]	 	$	[***]
	6/30/05	 	$	[***]	 	$	[***]	 	[***]	%	$	[***]	 	$	[***]	 	$	[***]	 	$	[***]
	9/30/05	 	$	[***]	 	$	[***]	 	[***]	%	$	[***]	 	$	[***]	 	$	[***]	 	$	[***]
	12/31/05	 	$	[***]	 	$	[***]	 	[***]	%	$	[***]	 	$	[***]	 	$	[***]	 	$	[***]
	3/31/06	 	$	[***]	 	$	[***]	 	[***]	%	$	[***]	 	$	[***]	 	$	[***]	 	$	[***]
	6/30/06	 	$	[***]	 	$	[***]	 	[***]	%	$	[***]	 	$	[***]	 	$	[***]	 	$	[***]
	10/2/06	 	$	[***]	 	$	[***]	 	[***]	%	$	[***]	 	$	[***]	 	$	[***]	 	$	[***]
	12/31/06	 	$	[***]	 	$	[***]	 	[***]	%	$	[***]	 	$	[***]	 	$	[***]	 	$	[***]

        [***]
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS. 

12

QuickLinks

TERM SHEET

EXHIBIT A before The honorable Charles B. Renfrew, arbitrator

EXHIBIT B before The honorable Charles B. Renfrew, arbitrator

EXHIBIT C REFUND SCHEDULE AND ADJUSTED ROYALTY RATES

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]